All About Multiple Sclerosis

More MS news articles for January 2004

Antisense Therapeutics CEO Mark Diamond to be Featured Guest on Biotech Today Radio Program

Tuesday January 13, 2004
Source: Antisense Therapeutics Limited

Antisense Therapeutics Limited (ASX: ANP - News), a biopharmaceutical company today announced that CEO Mark Diamond is scheduled to appear as a featured guest on Biotech Today, a New Media Internet radio show carried by World Talk Radio. The interview will air live at 4:20 PM ET on Wednesday, January 14. The live and archived broadcast can be accessed at the following Internet link: .

On the program, Mr. Diamond will discuss the Company's mission, business model, market opportunity, and lead compounds, which target Multiple Sclerosis and Psoriasis. Antisense Therapeutics has a strategic partnership with Isis Pharmaceuticals (Nasdaq: ISIS - News), which is also a major shareholder in the Company. Antisense Therapeutics has access to Isis's most advanced second-generation antisense chemistry to develop and commercialize select antisense compounds.

Antisense Therapeutics is currently undertaking a Phase I clinical trial of ATL1102 for Multiple Sclerosis. ATL1102 is an antisense inhibitor of VLA-4 (Very Late Antigen-4). Inhibition of VLA-4 has been shown to have positive effects in multiple animal models of inflammatory diseases, including MS.

About Antisense Therapeutics Limited

Antisense Therapeutics Limited is an Australian publicly listed biopharmaceutical drug discovery and development company. ANP's mission is to create, develop and commercialise novel antisense pharmaceuticals for large unmet markets. Its two most advanced projects target Multiple Sclerosis (ATL1102), and Psoriasis (ATL1101).

ANP plans to commercialise its pipeline via licensing/collaboration agreements with major biotechnology and pharmaceutical companies. ANP's major shareholders include Circadian Technologies Limited (ASX: CIR - News), Isis Pharmaceuticals Inc (Nasdaq: ISIS - News), Queensland Investment Corporation and the Murdoch Childrens Research Institute.

Further company details are available on the Antisense Therapeutics website:

Copyright © 2004, PRNewswire